KY61559X1045
© BusinessWire
13.12.2025
MLTX
LISTED
NASDAQ
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired MoonLake Immunotherapeutics ("MoonLake" or the Company") (NASDAQ: MLTX) securities between March 10, 2024 and September 29, 2025, inc...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
MLTX
LISTED
NASDAQ
MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
News Preview
Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025.
The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
MLTX
LISTED
NASDAQ
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at MoonLake Immunotherapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. (“MoonLake” or the “Company”) (NASDAQ: MLTX).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
05.11.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
News Preview
ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at an offering pr...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
05.11.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
News Preview
ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the third quarter of 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
MLTX
LISTED
NASDAQ
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclus...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
MLTX
LISTED
NASDAQ
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
IF...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
MLTX
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
MLTX
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclus...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
MLTX
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
MLTX
LISTED
NASDAQ
MLTX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake’s executi...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
MLTX
LISTED
NASDAQ
Securities Fraud Investigation Into MoonLake Immunotherapeutics (MLTX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MOONLAKE (MLTX) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM T...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
18.10.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE (MLTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIA...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
MLTX
LISTED
NASDAQ
Securities Fraud Investigation Into MoonLake Immunotherapeutics (MLTX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
MLTX
LISTED
NASDAQ
MLTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake and certain of MoonLake’s executives wit...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
MLTX
LISTED
NASDAQ
Rosen Law Firm Urges MoonLake Immunotherapeutics (NASDAQ: MLTX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”). MoonLake is a clinical-stage biotechnology company....
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
News Preview
The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of MLTX d...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
MLTX
LISTED
NASDAQ
MoonLake Investor News: Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MLTX
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public.
So What: If you purchased MoonLake s...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or f...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
MLTX
LISTED
NASDAQ
MLTX INVESTIGATION ALERT: MoonLake Immunotherapeutics Trial Results Triggers Securities Fraud Investigation after Stock Plummets 90% -- Investors Urged to Contact BFA Law
News Preview
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws.
If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics.
Wh...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
MLTX
LISTED
NASDAQ
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of mill...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.09.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
News Preview
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
MLTX
LISTED
NASDAQ
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
News Preview
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the l...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2025
MLTX
LISTED
NASDAQ
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2024
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
News Preview
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
News Preview
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
